Wegovy and Ozempic are both GLP-1 receptor agonists used to treat type 2 diabetes and obesity. According to the sources provided, it is difficult to determine which medication is more effective as they have not been directly compared in clinical trials.

Wegovy, also known as semaglutide, was approved by the FDA in June 2021 for the treatment of obesity. It works by mimicking the effects of a hormone called GLP-1, which helps to regulate blood sugar levels and reduce appetite. Wegovy is administered once a week by injection and has been shown to help patients lose significant amounts of weight [1].

Ozempic, also a GLP-1 receptor agonist, was approved by the FDA in December 2017 for the treatment of type 2 diabetes. It is also administered once a week by injection and has been shown to improve blood sugar control and promote weight loss [2].

Both medications have similar mechanisms of action and have been shown to be effective in clinical trials. However, they have different dosing regimens and may have different side effect profiles. According to GoodRx, the cost of Wegovy is higher than Ozempic, but both medications may be covered by insurance [3].

In conclusion, both Wegovy and Ozempic are effective medications for the treatment of type 2 diabetes and obesity. It is difficult to determine which medication is more effective as they have not been directly compared in clinical trials. The choice between the two medications may depend on factors such as dosing frequency, cost, and individual patient preferences. Patients should consult with their healthcare provider to determine which medication is best for their individual needs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://ro.co/health-guide/wegovy-vs-ozempic/
[3] https://www.goodrx.com/classes/glp-1-agonists/wegovy-vs-ozempic